SCHEMBL5775615

SCHEMBL5775615

CN(CCO)c1ccc(C=NNc2ccc(-c3cnco3)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 2/20 0.51
NPC1 O15118 5/20 0.48
RAB9A P51151 4/20 0.48
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
KLF5 Q13887 2/20 0.48
MPO P05164 1/20 0.41
IMPDH2 P12268 2/20 0.37
IMPDH1 P20839 1/20 0.37
AAK1 Q2M2I8 1/20 0.37
NOX3 Q9HBY0 1/20 0.37
NOX4 Q9NPH5 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
PSMD14 O00487 1/20 0.37
ALPL P05186 1/20 0.37
ALPI P09923 1/20 0.37
ALPG P10696 1/20 0.37
PKM P14618 3/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5775613 1.00 NOX1 (0.51) NOX1NPC1RAB9AKMT2AMEN1
SCHEMBL5777817 0.90 MPO (0.44) NOX1NPC1RAB9AKMT2AMEN1
SCHEMBL5777819 0.90 MPO (0.44) NOX1NPC1RAB9AKMT2AMEN1
SCHEMBL5779475 0.86 IMPDH2 (0.36) NOX1NPC1RAB9AKMT2AMEN1
SCHEMBL5778831 0.86 MPO (0.56) NOX1NPC1RAB9AKMT2AMEN1
SCHEMBL5778833 0.86 MPO (0.56) NOX1NPC1RAB9AKMT2AMEN1
SCHEMBL5779782 0.81 LMNA (0.40) NPC1RAB9AKMT2AMEN1MPO
SCHEMBL5779785 0.81 LMNA (0.40) NPC1RAB9AKMT2AMEN1MPO
SCHEMBL5779459 0.80 NPC1 (0.46) NOX1NPC1RAB9AKMT2AMEN1
SCHEMBL5779271 0.80 NPC1 (0.47) NPC1RAB9AKMT2AMEN1IMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 US disclosed
EP-1612204-A1 HYDRAZONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT NOX1 1745/4885NPC1 952/4885RAB9A 3127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.